Bispecific antibody drug conjugates:Making 1+1>2  

作　　者：Yilin Gu Zhijia Wang Yuxi Wang 

机构地区：[1]Targeted Tracer Research and Development Laboratory,Institute of Respiratory Health,Frontiers Science Center for Disease-Related Molecular Network,National Clinical Research Center for Geriatrics,West China Hospital,Sichuan University,Chengdu 610041,China [2]Frontiers Medical Center,Tianfu Jincheng Laboratory,Chengdu 610212,China

出　　处：《Acta Pharmaceutica Sinica B》2024年第5期1965-1986,共22页药学学报（英文版）

基　　金：This review was supported by the National Natural Science Foundation of China(82073318);Sichuan Science and Technology Program(2019YFS0003,China);the Support Program of Science&Technology Department of Sichuan Provincial(2023YFSY0046 and 2022NSFSC1365,China).

摘　　要：Bispecific antibody‒drug conjugates(BsADCs)represent an innovative therapeutic category amalgamating the merits of antibody‒drug conjugates(ADCs)and bispecific antibodies(BsAbs).Positioned as the next-generation ADC approach,BsADCs hold promise for ameliorating extant clinical challenges associated with ADCs,particularly pertaining to issues such as poor internalization,off-target toxicity,and drug resistance.Presently,ten BsADCs are undergoing clinical trials,and initial findings underscore the imperative for ongoing refinement.This review initially delves into specific design considerations for BsADCs,encompassing target selection,antibody formats,and the linker–payload complex.Subsequent sections delineate the extant progress and challenges encountered by BsADCs,illustrated through pertinent case studies.The amalgamation of BsAbs with ADCs offers a prospective solution to prevailing clinical limitations of ADCs.Nevertheless,the symbiotic interplay among BsAb,linker,and payload necessitates further optimizations and coordination beyond a simplistic“1+1”to effectively surmount the extant challenges facing the BsADC domain.

关 键 词：Bispecific antibody drug conjugates Antibody drug conjugates Bispecific antibody Targeted therapy SAFETY HER2 EGFR 

分 类 号：R730.53[医药卫生—肿瘤]